Skip to main content
    C

    Calidi Biotherapeutics Inc. (CLDI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.60
    -0.02 (-2.93%)

    Market Cap: $2.29M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Calidi Biotherapeutics Inc. (CLDI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Calidi Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.06M, operating cash flow was -$21.29M and free cash flow was -$21.41M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.65M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $20.24M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$449.00KN/A79.1%-2334.5%-2435.0%
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Revenue$0$0$0$0$449.00K$0
    Cost of revenue$0$0$0$0$94.00K$0
    Gross profit$0$0$0$0$355.00K$0
    Research and development$9.74M$8.88M$13.01M$0$4.67M$3.18M
    Operating income-$20.24M-$21.78M-$28.99M-$23.13M-$10.48M-$6.77M
    Net income-$20.06M-$22.21M-$29.22M-$25.43M-$10.93M-$7.94M
    EBITDA-$18.43M-$19.68M-$25.97M-$22.75M-$9.45M-$6.67M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.50M$0$0$0$0
    Gross profit$0$0$0-$423.00K$0$0$0-$393.00K$0$0$0-$364.00K
    Operating income-$4.34M-$4.15M-$4.19M-$4.47M-$5.05M-$5.66M-$5.06M-$4.03M-$5.23M-$5.77M-$6.75M-$9.82M
    Net income-$3.65M-$4.16M-$4.11M-$4.06M-$5.18M-$5.76M-$5.06M-$4.15M-$5.07M-$5.77M-$7.22M-$8.23M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $2.12M by $3.48M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$8.86M$14.18M$10.02M$2.60M$231.77M$1.85M
    Current assets$6.26M$10.23M$4.30M$786.00K$1.48M$513.00K
    Cash and equivalents$5.60M$9.59M$1.95M$372.00K$1.06M$420.00K
    Total liabilities$5.10M$12.21M$18.25M$43.44M$16.45M$24.33M
    Short-term debt$1.52M$223.00K$0$4.27M$0$5.28M
    Long-term debt$600.00K$600.00K$2.06M$0N/A$6.37M
    Shareholder equity$3.76M$1.53M-$8.23M-$50.44M-$14.69M-$22.48M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$5.52M$7.20M$9.59M$8.86M$14.03M$9.35M$15.06M$14.18M$6.66M$6.43M$7.41M$10.02M
    Total liabilities$3.89M$4.07M$4.66M$5.10M$6.83M$7.28M$7.76M$12.21M$16.45M$18.18M$21.98M$18.25M
    Cash and equivalents$3.95M$4.07M$6.63M$5.60M$10.38M$5.28M$10.56M$9.59M$1.90M$836.00K$1.14M$2.05M
    Shareholder equity$1.63M$3.13M$4.93M$3.76M$6.92M$1.76M$6.94M$1.53M-$10.28M-$11.75M-$14.57M-$8.23M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$21.29M-$19.69M-$26.98M-$13.21M-$7.77M-$4.83M
    Capital expenditures$120.00K$16.00K$585.00K$428.00K$206.00K$351.00K
    Free cash flow-$21.41M-$19.71M-$27.57M-$13.64M-$7.98M-$5.18M
    Dividends paid$5.67M$1.67MN/AN/AN/AN/A
    Investing cash flow-$170.00K-$16.00K-$478.00K-$494.00K-$215.00K-$388.00K
    Financing cash flow$17.46M$27.36M$29.04M$12.09M$9.81M$4.70M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.34M-$4.35M-$4.12M-$5.04M-$4.24M-$4.88M-$7.13M-$5.42M-$4.95M-$5.49M-$3.83M-$5.19M
    Capital expenditures$24.00K$33.00K$5.00K$29.00K$27.00K$57.00K$7.00K$5.00K$6.00K$5.00K$5.00K$70.00K
    Free cash flow-$2.36M-$4.39M-$4.12M-$5.07M-$4.26M-$4.94M-$7.14M-$5.43M-$4.95M-$5.50M-$3.84M-$5.26M
    Last 12 quarters

    Frequently Asked Questions About CLDI

    What is Calidi Biotherapeutics' annual revenue?

    Calidi Biotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Calidi Biotherapeutics profitable?

    No. Calidi Biotherapeutics reported net income of -$20.06M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does CLDI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$21.29M minus capital expenditures of $120.00K produced free cash flow of -$21.41M.

    How much debt does Calidi Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $600.00K, short-term debt of $1.52M and cash and equivalents of $5.60M.